Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Bioorg Med Chem ; 18(3): 1280-7, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20044261

ABSTRACT

Botulinum neurotoxins (BoNTs) are the etiological agents responsible for botulism, a disease characterized by peripheral neuromuscular blockade and a characteristic flaccid paralysis of humans. The natural product toosendanin, a limonoid, is a traditional Chinese medicine that has reported anti-botulinum properties in animal models. Toosendanin effectively inhibits the biological activity of BoNT/A in neuronal cells at concentrations of 200 nM, and partial inhibition can be observed with concentrations as low as 8 nM. Mechanistically, toosendanin's inhibition is due to prevention of transduction of the BoNT LC through the HC channel. Intriguing questions as to the molecular architecture of toosendanin as related to its anti-botulinum properties have focused our attention on a synthesis of toosendanin's unusual AB-ring, containing a unique bridged hemi-acetal. Within the current work, a synthetic strategy allowing access to the AB-fragment of toosendanin was achieved from a trans-decalin system. In addition, this fragment was examined for its modulation of BoNT/A intoxication in a rat spinal cord cellular assay.


Subject(s)
Botulinum Toxins, Type A/antagonists & inhibitors , Botulism/drug therapy , Drugs, Chinese Herbal/chemical synthesis , Drugs, Chinese Herbal/pharmacology , Animals , Botulinum Toxins, Type A/isolation & purification , Cell Culture Techniques , Clostridium botulinum/chemistry , Drugs, Chinese Herbal/chemistry , Humans , Rats , Spinal Cord/cytology
2.
Proc Natl Acad Sci U S A ; 106(5): 1330-5, 2009 Feb 03.
Article in English | MEDLINE | ID: mdl-19164566

ABSTRACT

Clostridium botulinum neurotoxin (BoNT) is the causative agent of botulism, a neuroparalytic disease. We describe here a semisynthetic strategy to identify inhibitors based on toosendanin, a traditional Chinese medicine reported to protect from BoNT intoxication. Using a single molecule assay of BoNT serotypes A and E light chain (LC) translocation through the heavy chain (HC) channel in neurons, we discovered that toosendanin and its tetrahydrofuran analog selectively arrest the LC translocation step of intoxication with subnanomolar potency, and increase the unoccluded HC channel propensity to open with micromolar efficacy. The inhibitory profile on LC translocation is accurately recapitulated in 2 different BoNT intoxication assays, namely the mouse protection and the primary rat spinal cord cell assays. Toosendanin has an unprecedented dual mode of action on the protein-conducting channel acting as a cargo-dependent inhibitor of translocation and as cargo-free channel activator. These results imply that the bimodal modulation by toosendanin depends on the dynamic interactions between channel and cargo, highlighting their tight interplay during the progression of LC transit across endosomes.


Subject(s)
Botulinum Toxins/antagonists & inhibitors , Animals , Botulinum Toxins/metabolism , Cells, Cultured , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/pharmacology , Female , Mice , Patch-Clamp Techniques , Protein Transport , Rats , Spinal Cord/cytology , Spinal Cord/drug effects , Spinal Cord/physiology
3.
Bioorg Med Chem ; 17(3): 1152-7, 2009 Feb 01.
Article in English | MEDLINE | ID: mdl-19131252

ABSTRACT

Botulinum neurotoxins (BoNTs) are the etiological agents responsible for botulism, a disease characterized by peripheral neuromuscular blockade and a characteristic flaccid paralysis of humans. The natural product toosendanin is a traditional Chinese medicine which has been reported to have anti-botulinum properties in animal models. To establish what chemical functionalities are necessary for the anti-botulinum properties found within toosendanin, a study was initiated with the goal of using function-oriented synthesis (FOS) as a strategy to begin to unravel toosendanin's powerful anti-botulinum properties. From these studies a new synthetic strategy is put forth allowing access to a 4-acetoxy CD fragment analogue (14) of toosendanin, which was achieved from mesityl oxide and acetylacetone in 14 steps. Animal studies on this fragment are also reported.


Subject(s)
Botulinum Toxins/antagonists & inhibitors , Drugs, Chinese Herbal/chemical synthesis , Animals , Botulism/drug therapy , Clostridium botulinum/drug effects , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/pharmacology , Limonins/chemical synthesis , Limonins/chemistry , Medicine, Chinese Traditional , Mice
SELECTION OF CITATIONS
SEARCH DETAIL